Follow
N. Arvind Dasari
N. Arvind Dasari
Other namesDasari A, N. Arvind Dasri
University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States
A Dasari, C Shen, D Halperin, B Zhao, S Zhou, Y Xu, T Shih, JC Yao
JAMA oncology 3 (10), 1335-1342, 2017
32582017
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ...
Journal of clinical oncology 33 (34), 4032-4038, 2015
7702015
Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018
JM Loree, S Anand, A Dasari, JM Unger, A Gothwal, LM Ellis, ...
JAMA oncology 5 (10), e191870-e191870, 2019
4812019
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study
DM Halperin, C Shen, A Dasari, Y Xu, Y Chu, S Zhou, YCT Shih, JC Yao
The Lancet Oncology 18 (4), 525-534, 2017
3872017
Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes
JM Loree, AAL Pereira, M Lam, AN Willauer, K Raghav, A Dasari, ...
Clinical Cancer Research 24 (5), 1062-1072, 2018
3412018
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
A Dasari, VK Morris, CJ Allegra, C Atreya, AB Benson III, P Boland, ...
Nature reviews Clinical oncology 17 (12), 757-770, 2020
3052020
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
MP Morelli, MJ Overman, A Dasari, SMA Kazmi, T Mazard, E Vilar, ...
Annals of Oncology 26 (4), 731-736, 2015
2852015
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
AW Tolcher, WA Messersmith, SM Mikulski, KP Papadopoulos, EL Kwak, ...
Journal of clinical oncology 30 (19), 2348-2353, 2012
2802012
Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives
M Aapro, P Bossi, A Dasari, L Fallowfield, P Gascón, M Geller, K Jordan, ...
Supportive care in cancer 28, 4589-4612, 2020
2612020
Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1–mediated activation of two GC-rich …
A Dasari, JN Bartholomew, D Volonte, F Galbiati
Cancer research 66 (22), 10805-10814, 2006
2582006
Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?
S Das, A Dasari
Current oncology reports 23, 1-7, 2021
2432021
Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases
A Dasari, K Mehta, LA Byers, H Sorbye, JC Yao
Cancer 124 (4), 807-815, 2018
2392018
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014
WA Messersmith, GI Shapiro, JM Cleary, A Jimeno, A Dasari, B Huang, ...
Clinical Cancer Research 21 (1), 60-67, 2015
2332015
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
CM Parseghian, JM Loree, VK Morris, X Liu, KK Clifton, S Napolitano, ...
Annals of Oncology 30 (2), 243-249, 2019
2072019
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
A Dasari, S Lonardi, R Garcia-Carbonero, E Elez, T Yoshino, A Sobrero, ...
The Lancet 402 (10395), 41-53, 2023
1512023
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
V Morris, MJ Overman, ZQ Jiang, C Garrett, S Agarwal, C Eng, B Kee, ...
Clinical colorectal cancer 13 (3), 164-171, 2014
1512014
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
A De Jesus-Acosta, D Laheru, A Maitra, J Arcaroli, MA Rudek, A Dasari, ...
Investigational new drugs 32, 739-745, 2014
1102014
Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors
K Ludford, WJ Ho, JV Thomas, KPS Raghav, MB Murphy, ND Fleming, ...
Journal of Clinical Oncology 41 (12), 2181-2190, 2023
1092023
Who should get lateral pelvic lymph node dissection after neoadjuvant chemoradiation?
S Malakorn, Y Yang, BK Bednarski, H Kaur, YN You, EB Holliday, ...
Diseases of the Colon & Rectum 62 (10), 1158-1166, 2019
1032019
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
N Vijayvergia, A Dasari, M Deng, S Litwin, T Al-Toubah, RK Alpaugh, ...
British journal of cancer 122 (9), 1309-1314, 2020
1022020
The system can't perform the operation now. Try again later.
Articles 1–20